Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper (ABIN5668226)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)], Human IgG1, kappa
-
Spezifität
- Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30 % of invasive breast cancers and 70 % of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder.
-
Produktmerkmale
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
Aufreinigung
- Protein A affinity purified
-
Reinheit
- > 98 % as determined by SDS-PAGE
-
Endotoxin-Niveau
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
-
Immunogen
- A431 cells (human epidermoid carcinoma) (over)expressing EGFR.
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
- This antibody binds to erbB-2/Her-2/neu has therapeutic indications particularly in the treatment of breast cancer (c.f. Herceptin). It can also be used to detect HER-2 by flow cytometry or IHC (Glazyrin 2007).
-
Kommentare
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS with 0.02 % Proclin 300.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
- ErbB2/Her2 (Trastuzumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- CD340, Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, p185HER2, EGFR
-
UniProt
- P04626
Target
-